MedinCell announces its participation in the Jefferies London Healthcare Conference 2022, 15-17 November in London
November 8, 2022
November 8, 2022
MedinCell announces the initiation of Phase 3 study of F14 (mdc-CWM), a therapeutic first-in-class that aims to provide weeks of localized pain relief after Total Knee Replacement
November 7, 2022
November 7, 2022
MedinCell’s partner Teva today announced refiling for approval of mdc-IRM and confirmed planned launch in the U.S. in H1 2023
November 3, 2022
November 3, 2022
MedinCell signs a licence agreement with the Medicines Patent Pool to fight malaria transmission, as part of its global health mission
September 13, 2022
September 13, 2022
MedinCell secures additional 20 million euros financing with the European Investment Bank (EIB)
September 5, 2022
September 5, 2022
Phase 3 study to be initiated for second long-acting injectable antipsychotic using MedinCell’s technology
August 29, 2022
August 29, 2022
An impact company committed to improving the health of patients worldwide, MedinCell publishes its 2021-2022 ESG annual report
August 17, 2022
August 17, 2022
Participation terms in the Combined General Meeting
August 8, 2022
August 8, 2022
MedinCell announces the availability of its 2021/2022 Universal Registration Document including the Annual Financial Report
July 29, 2022
July 29, 2022
MedinCell’s partner Teva confirms expectation for approval and commercialization in the US in H1 2023 for mdc-IRM/TEV46000
